iDose secures FDA approval
Glaukos’ New Drug Application for iDose TR (travoprost 75µg intracameral implant) has been approved by the FDA. The approval of iDose, a prostaglandin analogue indicated for the reduction of i
Staff reporters1 min read
Ophthalmology News
Positive results for new dry eye treatment
Alcon has announced positive topline results from two pivotal phase 3 clinical trials (Comet-2 and Comet-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symp
Staff reporters2 min read
VOSO’s Tongan travels
For the first time since the pandemic, Volunteer Ophthalmic Services Overseas’ (VOSO’s) chair Dr Andrew Riley and I made a five-day visit to Nuku'alofa in Tonga in September. A regular volunteer, this
Kylie Dreaver2 min read
Smart CL for keratoconus?
Belgian start-up Azalea Vision has successfully demonstrated its first functional prototype of smart contact lens Alma, designed to offer a non-surgical solution for patients suffering from keratoconu
Staff reporters2 min read
Breakthrough automation, from tonometry to lensmeters
Taking pride of place among a wealth of larger technologies on Device Technologies’ stand was Reichert’s Tono-Vera tonometer.
Staff reporters2 min read
Glaucoma: seniors’ unseen foe
Almost 3% of 70-year-olds in a Swedish study were unaware they had glaucoma.
Staff reporters1 min read
Fixing fixation for more accurate perimetry
The new iCare Compass automated perimeter with active retinal tracking, now with new features, is designed to optimise clinic efficiency and clinical care, while ensuring accuracy, said iCare's Yuka Ishida.
Staff reporters2 min read
Poster highlights: a snapshot of studies at RANZCO 2023
As ever, RANZCO’s poster area offered a glimpse into some of the work behind the scenes by the region’s ophthalmologists and clinical researchers, and included a healthy smattering from Aotearoa. Here are some that caught our eye.
Staff reporters4 min read
Promising Stargardt therapy revealed
The results of a 48-week trial of MCO-010, an intravitreal, adeno-associated virus (AAV2)-delivered optogenetic therapy, on Stargardt disease patients, showed significant improvements in visual acuity and reported no serious adverse effects, reported researchers from Nanoscope Therapeutics.
Staff reporters1 min read
Luxturna funding application stalls
Pharmac’s deferment of its decision to fund Luxturna (voretigene neparvovec), a gene therapy to treat RPE65 mutation-associated retinal dystrophy, is “disappointing”, said the University of Auckland’s
Drew Jones3 min read
Maintaining eye standards in ANZ
Product standards are written to ensure the things we use every day are safe and fit for purpose. But new rules mean New Zealand could fall behind...
Annette Hoskin3 min read
Making dry-eye assessment routine
Underpinning the advice an increasing number of ophthalmologists are putting into practice, Zeiss’ new Atlas 500 combines corneal topography and dry-eye assessment in one new piece of technology.
Staff reporters2 min read